Fluticasone propionate is under clinical development by NicOx and currently in the Phase II in clinical pathway. The characteristics of the clinical trial as well as other attributes related to the drug, regulations, and company play a fundamental role in ensuring the likelihood of transition that the drug moves from its current development stage to next.

According to GlobalData, the latest event to affect Fluticasone propionate’s likelihood of approval (LoA) and phase transition for Blepharitis took place on 24 Sep 2021, which decreased the likelihood that the drug progresses to the next phase in its clinical pathway.

GlobalData uses proprietary data and analytics to provide a complete picture of this assessment in their Fluticasone propionate Likelihood of Approval (LoA) and Phase Transition Success Rate (PTSR) Report.

Fluticasone propionate overview

Fluticasone propionate (NCX-4251, AC-155) is under development for the treatment of acute exacerbation of blepharitis and keratoconjunctivitis sicca (dry eye). The therapeutic candidate is a nanocrystalline form of fluticasone. The therapeutic candidate is administered through ophthalmic route as a suspension. The drug candidate is a synthetic trifluorinated corticosteroid with potent anti-inflammatory activity and acts by targeting glucocorticoid receptor (GR). It was also under development for the treatment of post-operative ocular inflammation and pain related to ophthalmology.

NicOx overview

NicOx is an ophthalmology company developing solutions to help maintain vision and improve ocular health. The company carries out the research, development and marketing of investigational drugs for ophthalmological diseases. The company aims to produce therapeutic products which aim to address the needs of eye care practitioners and patients. The company’s product pipeline includes NCX 470 for glaucoma and VYZULTA, ZERVIATE and NCX 4251 for blepharitis and dry eye disease. The company has a presence across Germany, France, the United Kingdom, Italy and Spain. NicOx is headquartered in Valbonne, France.

Quick View Fluticasone propionate LOA Data

Report Segments
  • Innovator
Drug Name
  • Fluticasone propionate
Administration Pathway
  • Ophthalmic
Therapeutic Areas
  • Central Nervous System
  • Ophthalmology
Key Developers
Highest Development Stage
  • Phase II

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.